Current status of DNA cytometry in osteosarcoma

Bauer, Henrik C. F.

doi:10.1007/978-1-4615-3518-8_18

Cited by 5 publications

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Osteosarcoma

Davis¹,

Wunder²,

Bell³

2014

TNM Online

View full text Add to dashboard Cite

Primary bone tumors are rare with an incidence of 2 to 3 per million, and of these, high‐grade osteosarcoma is the most common, representing 35% of all bone sarcomas. The typical patient diagnosed with osteosarcoma is male, between the ages of 10 and 20 years, and complains of pain for one to three months. The tumor is most commonly at the metaphysis of a long bone, with a predilection to the knee region. Dramatic improvements in disease‐free (DFS) and overall survival (OS) were demonstrated with the advent of doxorubicin and methotrexate chemotherapy regimes. The current standard of treatment for the patient with osteosarcoma is chemotherapy and resection of the primary tumor, most commonly preserving the limb. Despite the advances in radiological imaging, chemotherapy and surgery, 40 to 50% of patients will develop distant metastases and die of their disease. This chapter discusses the prognostic factors of disease outcome for osteosarcoma patients, specifically disease‐ or tumor‐related factors, host‐related factors, and environment‐ or treatment‐related factors.

show abstract

Osteosarcoma

Davis¹,

Wunder²,

Bell³

2014

TNM Online

View full text Add to dashboard Cite

show abstract

DNA and RNA content analysis by flow cytometry in the pathobiologic assessment of bone tumors

El‐Naggar

Hurr

et al. 1995

Cytometry

View full text Add to dashboard Cite

Studies of simultaneous DNA and RNA contents by flow cytometry in hematologic and some solid neoplasms have been shown to provide information that may be useful in the pathobiological evaluation of these neoplasms. We contend that similar analysis may be equally valuable in assessing bone tumors. Our data revealed significant statistical differences in DNA ploidy and proliferative fraction between benign and malignant bone neoplasms. Benign tumors manifested predominantly DNA diploidy and low proliferative activity, whereas the majority of malignant tumors were DNA aneuploid and showed high proliferation rate. No significant difference in the RNA content between different histopathologic categories was found. We observed, however, a distinct and consistently high RNA content pattern in giant cell tumors, aneurysmal bone cysts, and chondroblastomas that may be useful in their differential diagnosis. Analysis of different prognostic factors in malignant tumors indicated that histologic grade and DNA content are a significant prognostic factors. Further analysis of malignant tumors showed that a correlation between the proliferative activity and the clinical outcome in the low grade category and between RNA content and patients' survival in osteosarcomas. Our study also showed that preoperative treatment significantly impacted on the extent of the proliferative fraction in malignant tumors. We conclude that DNA/RNA analysis of bone tumor may assist in: (1) the differential diagnosis of certain bone tumors, (2) evaluation of treatment response, and (3) the biological assessment of osteosarcomas. o IWS w i~e y -u~~, Inc.

show abstract

Untersuchungstechniken

Knochenkrankheiten

View full text Add to dashboard Cite

Current status of DNA cytometry in osteosarcoma

Cited by 5 publications

References 32 publications

Osteosarcoma

Osteosarcoma

DNA and RNA content analysis by flow cytometry in the pathobiologic assessment of bone tumors

Untersuchungstechniken

Contact Info

Product

Resources

About